International Waldenstrom's Macroglobulinemia Foundation (IWMF)

The International Waldenstrom’s Macroglobulinemia Foundation ((IWMF) is a patient-founded and patient-led international nonprofit organization with a simple but compelling vision and mission.

OUR VISION: A world without WM (Waldenstrom’s macroglobulinemia)

OUR MISSION: Support and educate everyone affected by Waldenstrom’s macroglobulinemia (WM) while advancing the search for a cure

The IWMF is committed to creating a world without WM by finding a cure. Since 1999, the IWMF has invested over $18 million in WM research projects throughout the world. Thanks to this research WM patients have better treatment options that can lead to deeper, longer lasting remissions, and fewer side effects.

Latest from International Waldenstrom's Macroglobulinemia Foundation (IWMF)

The International Waldenstrom's Macroglobulinemia Foundation (IWMF) Is Proud to Announce Three Waldenstrom Macroglobulinemia (WM) Research Grant Opportunities

November 30, 2021

Article

Learn more about the latest IWMF research initiatives.

FDA Approval of Brukinsa in Rare Lymphoma Offers a New Option, Though Will Not Replace Other Therapies

September 22, 2021

Article

The FDA approval of Brukinsa represents another treatment option with fewer side effects in patients with Waldenstrom's macroglobulinema, however it will not serve as a replacement for other therapies.

26th Annual IWMF Educational Forum

August 22, 2021

Article

The Virtual Educational Forum is a unique opportunity to learn from medical experts and connect with WM community members around the world.

Presenting Emil Parente: Living With WM For 32 Years

September 10, 2015

Article

Emil Parente is a WMer with a real past, and he is happy to share it with others, particularly those who are newly diagnosed.

Living With WM: 17 Years And Going Strong

September 04, 2015

Article

Marguerite Regan tells her Waldenström's macroglobulinemia story.

First Drug Approved Specifically for Waldenström's Macroglobulinemia

January 30, 2015

Article

Ibrutinib becomes the first drug specifically approved for Waldenström's macroglobulinemia (WM), two months ahead of expectations.